Trivalent Ad26.Mos.HIV
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Trivalent Ad26.Mos.HIV, covering 2023-06-09 to 2023-06-09. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults [Phase 1, Phase 2]